Last updated on July 2018

Registry of Guardant360 Use and Outcomes In People With Advanced Cancer


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Non Small Cell Lung Cancer Metastatic
  • Age: Between 18 - 100 Years
  • Gender: Male or Female

General Inclusion Criteria:

  1. 18 Years of age or older
  2. Ability to provide written informed consent
  3. Blood collected for the most recent Guardant360 test within 8 weeks prior to enrollment

General Exclusion Criteria

  1. Pregnancy at the time of the qualifying Guardant360 blood collection
  2. History of the allogeneic organ or tissue transplant

Module 1 (Non-Small Cell Lung Cancer)

Inclusion Criteria

  1. NSCLC, confirmed by histology or cytology
  2. Advanced disease, defined as: stage IIIB or IV NSCLC at the time of the qualifying Guardant360 blood collection; or for subjects with an initial diagnosis of Stage I-IIIA disease, NSCLC that is recurrent or metastatic at the time of the qualifying Guardant360 blood collection
  3. One of the following conditions at the time of the qualifying Guardant360 blood
    collection
    • No prior systemic therapy for advanced disease OR
    • All three of the following conditions:
  4. A history of prior systemic therapy for advanced disease, 2. Disease progression within the previous four weeks, & 3. No new systemic therapy for advanced disease

Exclusion Criteria Subjects with a diagnosis or history of any cancer involving the lung that is not classified as NSCLC, including but not limited to small cell carcinoma, neuroendocrine or carcinoid tumor, lymphoma, mesothelioma, metastatic non-lung carcinoma, or cancer of unknown primary.

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.